January 29, 2015 8:33 AM ET

Healthcare Equipment and Supplies

Company Overview of Sera Prognostics, Inc.

Company Overview

Sera Prognostics, Inc., a biotechnology company, develops diagnostic and blood tests that help physicians to predict and manage preterm birth, preeclampsia, and other pregnancy complications. Sera Prognostics, Inc. has a strategic partnership with Agilent Technologies Inc. The company was founded in 2008 and is based in Salt Lake City, Utah.

2749 East Parleys Way

Suite 200

Salt Lake City, UT 84109

United States

Founded in 2008

Phone:

801-505-0278

Key Executives for Sera Prognostics, Inc.

Executive Chairman
Age: 61
Co-Founder and Co-Chairman of The Scientific Advisory Board
Co-Founder and Co-Chairman of Scientific Advisory Board
Chief Financial Officer
Age: 47
Compensation as of Fiscal Year 2014.

Sera Prognostics, Inc. Key Developments

Sera Prognostics, Inc. Appoints Mansoor Raza Mirza to Its Board of Directors

Sera Prognostics, Inc. announced the appointment of Mansoor Raza Mirza to its Board of Directors. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshospitalet - the Copenhagen University Hospital, Denmark. He currently serves as a director of Karyopharm Therapeutics and Metamark Genetics. Dr. Mirza chairs the Health Ministry's obligatory teaching course on non-surgical treatment of cancer for Danish doctors specializing in Clinical Oncology. He is vice-president of the Danish Gynecologic Cancer Group (DGCG) and medical director of Nordic Society of Gynecologic Oncology (NSGO).

Sera Prognostics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM

Sera Prognostics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Gregory C. Critchfield, Executive Chairman, Chief Executive Officer and President.

Agilent Technologies and Sera Prognostics Enter Strategic Partnership to Develop Proteomic Assays for Fetal and Maternal Health

Agilent Technologies Inc. and Sera Prognostics Inc. announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications. As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent's automated sample-preparation technologies for production. The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent's novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.

Similar Private Companies By Industry

Company Name Region
Allograft Tissue Systems, Inc. United States
Circuport, Inc. United States
O2 Plus United States
Neural Signals, Inc. United States
GenturaDx, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 7, 2014
--
Private Placement
May 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sera Prognostics, Inc., please visit www.seraprognostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.